126 related articles for article (PubMed ID: 16275679)
1. Acute toxicity and preliminary clinical outcomes of concurrent radiation therapy and weekly docetaxel and daily cisplatin for head and neck cancer.
Kitamoto Y; Akimoto T; Ishikawa H; Nonaka T; Katoh H; Nakano T; Ninomiya H; Chikamatsu K; Furuya N
Jpn J Clin Oncol; 2005 Nov; 35(11):639-44. PubMed ID: 16275679
[TBL] [Abstract][Full Text] [Related]
2. Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.
Tishler RB; Posner MR; Norris CM; Mahadevan A; Sullivan C; Goguen L; Wirth LJ; Costello R; Case M; Stowell S; Sammartino D; Busse PM; Haddad RI
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1036-44. PubMed ID: 16682134
[TBL] [Abstract][Full Text] [Related]
3. Prospective pilot study of consolidation chemotherapy with docetaxel and cisplatin after concurrent chemoradiotherapy for advanced head and neck cancer.
Lee KC; Lee SH; Lee Y; Park SH; Park J; Cho EK; Shin DB; Lee JH; Kim DY; Kim ST
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):187-91. PubMed ID: 17996392
[TBL] [Abstract][Full Text] [Related]
4. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
[TBL] [Abstract][Full Text] [Related]
5. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer.
Kovács AF; Mose S; Böttcher HD; Bitter K
Strahlenther Onkol; 2005 Jan; 181(1):26-34. PubMed ID: 15660190
[TBL] [Abstract][Full Text] [Related]
6. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
[TBL] [Abstract][Full Text] [Related]
7. Concurrent chemoradiotherapy with cisplatin and docetaxel for advanced head and neck cancer. A phase I study.
Inohara H; Inoue T; Akahani S; Yamamoto Y; Takenaka Y; Nakagawa T; Isohashi F; Kubo T
Anticancer Res; 2004; 24(6):4135-40. PubMed ID: 15736464
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck.
Tsao AS; Garden AS; Kies MS; Morrison W; Feng L; Lee JJ; Khuri F; Zinner R; Myers J; Papadimitrakopoulou V; Lewin J; Clayman GL; Ang KK; Glisson BS
J Clin Oncol; 2006 Sep; 24(25):4163-9. PubMed ID: 16943532
[TBL] [Abstract][Full Text] [Related]
9. A Phase II multi-institutional trial of chemoradiation using weekly docetaxel and erythropoietin for high-risk postoperative head and neck cancer patients.
Willey CD; Murphy BA; Netterville JL; Burkey BB; Shyr Y; Shakhtour B; Kish B; Raben D; Chen C; Song JI; Kane MA; Cmelak AJ
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1323-31. PubMed ID: 17289289
[TBL] [Abstract][Full Text] [Related]
10. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
[TBL] [Abstract][Full Text] [Related]
11. Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study.
Koukourakis MI; Tsoutsou PG; Karpouzis A; Tsiarkatsi M; Karapantzos I; Daniilidis V; Kouskoukis C
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):9-15. PubMed ID: 19744802
[TBL] [Abstract][Full Text] [Related]
12. Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer.
Watkins JM; Zauls AJ; Wahlquist AH; Shirai K; Garrett-Mayer E; Gillespie MB; Day TA; Sharma AK
Laryngoscope; 2010 Feb; 120(2):236-42. PubMed ID: 19950378
[TBL] [Abstract][Full Text] [Related]
13. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
Schwartz DL; Montgomery RB; Yueh B; Donahue M; Anzai Y; Canby R; Buelna R; Anderson L; Boyd C; Hutson J; Keegan K
Cancer; 2005 Jun; 103(12):2534-43. PubMed ID: 15856475
[TBL] [Abstract][Full Text] [Related]
14. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
15. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
Tishler RB; Norris CM; Colevas AD; Lamb CC; Karp D; Busse PM; Nixon A; Frankenthaler R; Lake-Willcutt B; Costello R; Case M; Posner MR
Cancer; 2002 Oct; 95(7):1472-81. PubMed ID: 12237916
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
Ghi MG; Paccagnella A; D'Amanzo P; Mione CA; Fasan S; Paro S; Mastromauro C; Carnuccio R; Turcato G; Gatti C; Pallini A; Nascimben O; Biason R; Oniga F; Medici M; Rossi F; Fila G
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):481-7. PubMed ID: 15145166
[TBL] [Abstract][Full Text] [Related]
17. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
Maguire PD; Meyerson MB; Neal CR; Hamann MS; Bost AL; Anagnost JW; Ungaro PC; Pollock HD; McMurray JE; Wilson EP; Kotwall CA
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):698-704. PubMed ID: 14967423
[TBL] [Abstract][Full Text] [Related]
18. Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial.
Hehr T; Classen J; Belka C; Welz S; Schäfer J; Koitschev A; Bamberg M; Budach W
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1423-31. PubMed ID: 15817346
[TBL] [Abstract][Full Text] [Related]
19. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Katori H; Tsukuda M; Watai K
Cancer Chemother Pharmacol; 2007 Aug; 60(3):399-406. PubMed ID: 17096160
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
Iwasaki Y; Ohsugi S; Natsuhara A; Tsubokura T; Harada H; Ueda M; Arimoto T; Hara H; Yamada T; Takesako T; Kohno K; Hosogi S; Nakanishi M; Marunaka Y; Nishimura T
Cancer Chemother Pharmacol; 2006 Dec; 58(6):735-41. PubMed ID: 16565832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]